Caplin Point Laboratories (NSE:CAPLIPOINT) Cyclically Adjusted Revenue per Share: ₹183.99 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:CAPLIPOINT Caplin Point Laboratories Ltd NSE:CAPLIPOINT
88 GF Score
Price ₹2,614.20
GF Value ₹2,090.78
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Caplin Point Laboratories Cyclically Adjusted Revenue per Share?

Caplin Point Laboratories NSE:CAPLIPOINT -2.14% 88 Cyclically Adjusted Revenue per Share is ₹183.99 as of Mar. 2026. GuruFocus rates NSE:CAPLIPOINT with a GF Score™ of 88/100 and a GF Value™ of ₹2,090.78 (Modestly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Caplin Point Laboratories's adjusted revenue per share for the three months ended in Mar. 2026 was ₹78.712. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹183.99 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Caplin Point Laboratories's average Cyclically Adjusted Revenue Growth Rate was 18.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 19.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 21.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Caplin Point Laboratories was 23.50% per year. The lowest was 19.50% per year. And the median was 21.60% per year.

As of today (2026-07-18), Caplin Point Laboratories's current stock price is ₹2614.20. Caplin Point Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₹183.99. Caplin Point Laboratories's Cyclically Adjusted PS Ratio of today is 14.21.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Caplin Point Laboratories was 17.91. The lowest was 5.54. And the median was 9.73.


Caplin Point Laboratories  (NSE:CAPLIPOINT) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Caplin Point Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2614.20/183.99
=14.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Caplin Point Laboratories was 17.91. The lowest was 5.54. And the median was 9.73.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Caplin Point Laboratories Cyclically Adjusted Revenue per Share Related Terms


Caplin Point Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Caplin Point Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caplin Point Laboratories Cyclically Adjusted Revenue per Share Chart

Caplin Point Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 86.05 107.65 130.53 154.79 183.99

Caplin Point Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 154.79 162.45 170.14 176.52 183.99

NSE:CAPLIPOINT vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Caplin Point Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Caplin Point Laboratories Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Caplin Point Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Caplin Point Laboratories's Cyclically Adjusted PS Ratio falls into.


NSE:CAPLIPOINT
88GF Score
Caplin Point Laboratories Ltd NSE:CAPLIPOINT
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Caplin Point Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Caplin Point Laboratories's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=78.712/164.2724*164.2724
=78.712

Current CPI (Mar. 2026) = 164.2724.

Caplin Point Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 11.261 105.961 17.458
201609 12.670 105.961 19.642
201612 13.626 105.196 21.278
201703 15.586 105.196 24.339
201706 16.283 107.109 24.973
201709 17.313 109.021 26.087
201712 18.642 109.404 27.991
201803 19.225 109.786 28.766
201806 19.252 111.317 28.411
201809 22.140 115.142 31.587
201812 20.926 115.142 29.855
201903 22.575 118.202 31.374
201906 24.764 120.880 33.654
201909 29.773 123.175 39.707
201912 29.929 126.235 38.947
202003 25.780 124.705 33.960
202006 31.479 127.000 40.717
202009 35.159 130.118 44.388
202012 36.012 130.889 45.197
202103 34.703 131.771 43.263
202106 39.224 134.084 48.055
202109 39.915 135.847 48.267
202112 42.695 138.161 50.764
202203 44.364 138.822 52.497
202206 45.313 142.347 52.292
202209 46.962 144.661 53.329
202212 49.026 145.763 55.252
202303 49.586 146.865 55.463
202306 51.790 150.280 56.612
202309 53.761 151.492 58.296
202312 57.188 152.924 61.432
202403 57.352 153.035 61.564
202406 60.124 155.789 63.398
202409 63.231 157.882 65.790
202412 64.529 158.323 66.954
202503 65.868 157.552 68.678
202506 66.883 159.755 68.774
202509 70.018 162.289 70.874
202512 71.241 163.281 71.674
202603 78.712 164.272 78.712

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹183.99 mean?
Caplin Point Laboratories (NSE:CAPLIPOINT) has a Cyclically Adjusted Revenue per Share of ₹183.99 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Caplin Point Laboratories and its competitors.
Is Caplin Point Laboratories' Cyclically Adjusted Revenue per Share too high?
Caplin Point Laboratories' current Cyclically Adjusted Revenue per Share is ₹183.99. Overall, Caplin Point Laboratories has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caplin Point Laboratories' Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Caplin Point Laboratories' Cyclically Adjusted Revenue per Share of ₹183.99 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Caplin Point Laboratories and its competitors. Caplin Point Laboratories's current Cyclically Adjusted Revenue per Share is ₹183.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caplin Point Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Caplin Point Laboratories (NSE:CAPLIPOINT) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,090.78, compared to a current price of ₹2,614.20 — trading 25% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹183.99. Caplin Point Laboratories' overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Caplin Point Laboratories (NSE:CAPLIPOINT), the current Cyclically Adjusted Revenue per Share is ₹183.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Caplin Point Laboratories (NSE:CAPLIPOINT) Overvalued in 2026?

Based on GuruFocus' analysis, Caplin Point Laboratories stock appears to be overvalued. The current stock price of ₹2,614.20 is trading 25% above its estimated GF Value™ of ₹2,090.78. GuruFocus considers Caplin Point Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:CAPLIPOINT:

  • Cyclically Adjusted Revenue per Share: ₹183.99
  • GF Value™: ₹2,090.78 vs. price of ₹2,614.20 (25% above fair value)
  • GF Score™: 88/100 with 5 warning signs

No single metric tells the full story. See the NSE:CAPLIPOINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Caplin Point Laboratories Business Description

Other Exchanges 524742:India
Address Ashvich Tower, Developed Plots Industrial Estate, No. 3, 3rd Floor, Perungudi, Chennai, TN, IND, 600 096
Caplin Point Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, injections (liquid and lyophilized, prefilled syringes), ophthalmic solutions, liquid orals, soft gel capsules, ointments, creams, gels, powders for injections, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops.
88GF Score

Get the complete analysis for NSE:CAPLIPOINT

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,614.20
Price
₹2,090.78
GF Value